When discussing "SLS" in the context of financial markets, it most commonly refers to SELLAS Life Sciences Group, Inc. (NasdaqCM: SLS), a late-stage clinical biopharmaceutical company based in the United States.1
Here's a breakdown of key information regarding SELLAS Life Sciences Group, Inc.:
Company Overview
SELLAS Life Sciences Group is dedicated to the development of novel cancer immunotherapies.1 Their lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center. GPS targets the Wilms Tumor 1 (WT1) protein, which is present in various tumor types, and has potential as a monotherapy or in combination with other immunotherapeutic agents for a broad spectrum of hematologic (blood) cancers and solid tumor indications.1
The company is also developing SLS009 (tambiciclib), a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, licensed from GenFleet Therapeutics. SLS009 is being investigated for its potential in various cancer indications, including acute myeloid leukemia (AML) patients with unfavorable prognostic factors.2
Financials and Recent Developments
As of March 31, 2025, SELLAS Life Sciences Group has incurred recurring losses and negative cash flows from operations, with an accumulated deficit of $253.9 million.2 For the three months ended March 31, 2025, the company reported a net loss of $5.8 million and used $9.1 million in cash from operations.2
The company has recently engaged in financing activities, including the exercise of existing warrants by institutional investors. For instance, in October 2025, warrants previously issued in March and August 2024 were exercised for approximately $31.0 million in gross proceeds.3 Similarly, in September 2025, warrants issued in January 2025 were exercised, generating approximately $23.6 million in gross proceeds.4 These transactions involved the issuance of new warrants to the investors.3
Analyst Sentiment and Price Targets
The average one-year price target for SELLAS Life Sciences Group is $6.97, with forecasts ranging from $6.06 to $7.88.5 Analysts consider the stock to be fairly valued at this price target based on projected earnings and historical performance.5
Institutional Ownership
SELLAS Life Sciences Group, Inc. has 67 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 15,186,623 shares.6 The institutional ownership has shown an increase of 114.77% quarter-over-quarter in institutional shares (long positions).6
Short Interest
As of recent data, the short interest for SLS is approximately 27.74 million shares, representing about 30.19% of the float. The days to cover stands at 19.25 days.1
For more detailed analysis, including SEC filings, institutional ownership trends, short interest data, and analyst forecasts, you can explore the dedicated Fintel page for SELLAS Life Sciences Group, Inc. (NasdaqCM: SLS).1
